In this context, endocan is postulated as a promising biomarker for the early diagnosis and prognosis of chronic inflammatory states, both in type 2 diabetes mellitus and periodontitis, due to its ability to reflect the endothelial activation associated with these conditions. Here, ESM1 is linked to diabetes mellitus.